Laporte Kathleen
SEC-identified person · CIK 1196201 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Q32 Bio Inc. QTTB | Director | filed 2024–2026 |
| Bolt Biotherapeutics, Inc. BOLT | Director | filed 2021–2026 |
| Transgenomic INC TBIOD | Director | filed 2018–2026 |
| Phoenix Biotech Acquisition Corp. PBAX | Director | filed 2021–2026 |
| 89bio, Inc. ETNB | Director | filed 2021–2025 |
| Affymax INC AFFY | Director | filed 2006–2012 |
| Transcept Pharmaceuticals Inc TSPT | Director | filed 2009–2012 |
| Ista Pharmaceuticals INC ISTA | Director | filed 2006–2011 |
| World Heart Corp whrt | Officer | filed 2008–2010 |
| Vnus Medical Technologies INC VNUS | Director | filed 2006–2008 |
| Ehealth, Inc. EHTH | Director | filed 2006–2006 |
| Adeza Biomedical Corp ADZA | Director | filed 2006–2006 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.